User talk:Boghog/Archive 19

Archive 15

←

Archive 17

Archive 18

Archive 19

Archive 20

Top Ten Medical Editor Barnstar 2024

Top 10	Top 10 Medical Editor Barnstar 2024
	You were one of the top medical editors on English in 2024. Thank you for your hard work! —Mvolz (talk) 15:52, 1 January 2025 (UTC)

Disambiguation link notification for January 4

An automated process has detected that when you recently edited Thyroxine, you added a link pointing to the disambiguation page Follicular cell.

(Opt-out instructions.) --DPL bot (talk) 19:57, 4 January 2025 (UTC)

FAR for Hippocampus

I have nominated Hippocampus for a featured article review here. Please join the discussion on whether this article meets the featured article criteria. Articles are typically reviewed for two weeks. If substantial concerns are not addressed during the review period, the article will be moved to the Featured Article Removal Candidates list for a further period, where editors may declare "Keep" or "Delist" in regards to the article's featured status. The instructions for the review process are here. Z1720 (talk) 00:13, 5 January 2025 (UTC)

Consistent citation formating

I have been doing a MAJOR overhaul of Vitamin D prior to nominating it for GA, and not done yet. Hope to be done by end of January, and then intend to leave it alone for a least a month to see if it stays stable. A request - at the end of February would you please run a citation formating check on the article? Of the approx 200 refs, half are from before I started this effort in November and half since then. Thanks. David notMD (talk) 21:28, 6 January 2025 (UTC)

@David notMD: Thanks for your amazing work on the Vit D article. I have a strong interest in nuclear receptors, so of course I will jump in and help when I can. Cheers. Boghog (talk) 19:49, 8 January 2025 (UTC)

Great on receptors, as not an area of my expertise. David notMD (talk) 19:59, 8 January 2025 (UTC)

Working on the entire Mechanim of action section in my sandbox. Once I patch that back into the article I will ask you to look at the receptors content. This effort has been one of taking an extended quilt of individual edits over years and converting all that into a more-recent-referenced coherent article that will be of use to first-time and repeat readers. (I hope.) Of all the vitamin articles, this one gets the most viewers. David notMD (talk) 16:17, 13 January 2025 (UTC)

Disambiguation link notification for January 21

An automated process has detected that you recently added links to disambiguation pages.

Vitamin D

added links pointing to CAMP, HLA, P27 and SPP1

(Opt-out instructions.) --DPL bot (talk) 19:54, 21 January 2025 (UTC)

Vitamin D

Thank you for contributing to the vitamin D article. I am going to step away for a month or two, then come back to it with fresh eyes, before nominating for GA review. Please continue to add and amend as you see fit in the interim. David notMD (talk) 18:38, 22 January 2025 (UTC)

Viatris History

Hi Boghog. How are you? I see that you are a member of Wikipedia:WikiProject Pharmacology/Participants, therefore, I am hoping you might want to have a look at an edit request I posted for Viatris, a pharmaceutical company, at Talk:Viatris#History Section. It is a pretty simple edit that I hope you will be able to implement. If you have any questions, please get in touch. Thanks so much, ~~~~

PittGuy123ABC (talk) 15:48, 5 February 2025 (UTC)

Hi boghog

I had an inquiry to ask you but i'd rather not talk about it on here all i can say is there is alot of money involved in this. K109manlow (talk) 11:04, 9 March 2025 (UTC)

I assume this is about paid editing which I am not interested in. Thanks. Boghog (talk) 14:14, 10 March 2025 (UTC)

Disambiguation link notification for March 16

An automated process has detected that when you recently edited Evofosfamide, you added a link pointing to the disambiguation page Hypoxia.

(Opt-out instructions.) --DPL bot (talk) 19:56, 16 March 2025 (UTC)

Legend Status

		The Surreal Barnstar
		Your dedication and consistency are inspiring. Serious legendary contributions to society. Respect. Summerfell1978 (talk) 17:31, 17 March 2025 (UTC)

Thanks Summerfell1978. "Legendary contributions to society" might be a bit of an overstatement though (I’m just here trying not to break things too much), but I truly appreciate the kind words. Respect right back at you! Boghog (talk) 04:31, 18 March 2025 (UTC)

RE Tapentadol article

Hello @Boghog! We spoke recently about the tapentadol article. I have written a rough draft for the introductory section on the page. I haven't published it yet, and figured we could speak about it here before publishing? Thank you so much for your kind words about my illness - it means the world to me. Due to said illness, I'm in quite significant pain, and hence need tapentadol, which has led to me editing the article (to get my mind off things).

I will attach the rough draft here:

Extended content

Tapentadol, sold under the brand names Nucynta and Palexia among others, is a synthetic opioid analgesic of the benzenoid class with a dual mode of action as a highly selective full agonist of the μ-opioid receptor and as a norepinephrine reuptake inhibitor (NRI). It is highly addictive and is a commonly abused drug. Tapentadol is used medically for the treatment of moderate to severe pain. Common side effects include euphoria, constipation, nausea, vomiting, headaches, loss of appetite, drowsiness, dizziness, itching, dry mouth, and sweating. Serious side effects may include addiction and dependence, substance abuse, respiratory depression and an increased risk of serotonin syndrome. Combining tapentadol with certain substances, including serotonin-based drugs or central nervous system depressants such as alcohol, cannabis, gabapentinoids, benzodiazepines, and other opioids, may increase the risk of serotonin syndrome, sedation, respiratory depression, and death. Analgesia occurs within 32 minutes of oral administration, and lasts for 4–6 hours. Tapentadol is taken by mouth, and is available in immediate-release and controlled-release formulations. Tapentadol – unlike tramadol – is not metabolised by the CYP enzymes. Instead, tapentadol is metabolised through a process known as glucuronidation. Due to this, tapentadol produces minimal metabolites, when compared with tramadol, which means that it has fewer drug-drug interactions, and that it causes fewer side effects. Tapentadol’s combined mechanism of action is often compared to that of tramadol. Like tramadol, tapentadol affects both the opioid system and the norepinephrine system to relieve pain. Unlike tramadol, it has only weak effects on the reuptake of serotonin and is a significantly more potent opioid with no known active metabolites.. The potency of tapentadol is somewhere between that of tramadol and morphine, with an analgesic efficacy comparable to that of oxycodone despite a lower incidence of side effects. In the late 1980s, Grünenthal developed tapentadol to improve on tramadol, which they created in the 1960s. Their goal was to design a molecule that minimized serotonin activity, strongly activated the μ-opioid receptor, inhibited norepinephrine reuptake, and worked without metabolic activation. The result was tapentadol. It is addictive, commonly abused, and carries a high risk of dependence. Its water solubility allows it to be snorted, inhaled, or used rectally, increasing abuse potential. As a result, it is a Schedule II controlled substance in the U.S., a Schedule 8 drug in Australia, and a Class A controlled substance in the UK.

I figured that the content matched what you think the page needs. I shortened it, made larger paragraphs (hence avoiding countless small paragraphs), fixed some wording and grammatical errors, and I tried to keep the references and citations accurate and matching the text they were supporting.

Please let me know what you think! I'll be really glad if we can come to a mutual decision about this - it's stressing me out a little. I hope that we can clean up the article and make it truly awesome and a joy to read. Feel free, of course, to send me any changes you would like for the introductory section. It would be great to get it published ASAP. Furthermore, we will need to try to match the references with the new text (I have a saved copy which links to articles on here and references, but still, it would be good to double check, and adding some, too). Gabavibes (talk) 00:19, 4 April 2025 (UTC)

@Gabavibes: Thank you so much for taking the time to work on restructuring the lead—especially while you’re going through such a difficult time. I’ve read through your draft, and I think it looks excellent. It’s clear, well-structured, and a definite improvement. I would fully support replacing the current lead with the version you've written.

Also, I just want to say again how much I admire your dedication, especially given the pain you’re dealing with. I hope the editing helps offer a bit of distraction, and please don’t hesitate to take things at whatever pace feels manageable. Wishing you some relief and comfort soon. Boghog (talk) 06:05, 4 April 2025 (UTC)

@Boghog Thank you so much! That's okay - again - it helps me to get my mind off things. My life really isn't great right now, as I said, so your kindness, empathy and warmth mean the world to me. Really, you're making a big difference in people's lives. I've just published the edited lead. Please have a look at it, and let me know if there are any changes you'd like! I'll try my best to keep up with it all, but have a few busy days coming up. Chat soon! Have a great weekend :) Gabavibes (talk) 07:16, 4 April 2025 (UTC)

@Boghog I hope you're having a nice weekend! Just letting you know that I am continuing to tinker away. I've rehauled the "adverse effects" section of the tapentadol article - including added content, along with dividing it into three sections with subheadings. Next - when I have time - I'll try to work on the "pharmacology" section (that will take me more time, broadly, splitting it into "mechanism of action" and "pharmacokinetics").

As I mentioned, more than happy, of course, for you to edit what I've done, or edit more broadly, the same goes for other users. I think it's already looking much better! I'm trying to bring it - overall - more in line with the wiki articles on morphine, oxycodone and tramadol (it makes the most sense to use those as a starting point).

Thanks so much again for your kind words and understanding, it means a lot to me! Gabavibes (talk) 07:28, 5 April 2025 (UTC)

Yunlong Cao

BTW: Draft:Yunlong Cao is with Comment: He needs to better establish himself in the international stage with both many more publications (and citations) plus major awards. I strongly suggest waiting until he becomes a full professor.
Under this standard, most of Nature's 10 are red. Htmlzycq (talk) 05:09, 17 April 2025 (UTC)

I think he is getting close. According to Google Scholar, he has published 52 arctics, 3 of which have been cited over 100 times each.

Article Request Earth BioGenome Project

Do you think it is necessary to establish separate articles for each sub project?

such as i5K (insects), B10K (birds), 10KP (plants), and the Darwin Tree of Life Htmlzycq (talk) 04:41, 17 April 2025 (UTC)

The subprojects are probably not notable enough to justify separate articles with the possible exception of the "Darwin Tree of Life" project. Boghog (talk) 05:54, 17 April 2025 (UTC)

1000 Plant Genomes Project (1KP) has articles, but 10KP doesn't, which is strange. Htmlzycq (talk) 07:27, 17 April 2025 (UTC)